JPRN-jRCTs041180098已完成未知
Study on Diagnosis of Alzheimer's disease with FDG-PET - SDAF-PET
Ito Kengo0 个研究点目标入组 138 人开始时间: 2019年3月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 138
研究概览
简要总结
The diagnostic performance of FDG-PET in the differential diagnosis of AD and FTLD is higher than that of p-tau181 in CSF. In addition, there is no problem with the safety of FDG-PET.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 55age old 至 <= 84age old（—）
- 性别
- All
入选标准
- •1)Patients with AD or FTLD whose native language is Japanese.
- •2)Patients signing written informed consent. If a patient is considered incapable of consenting, his/her legally acceptable representative is required to sign the consent form.
- •3)Patients with a study partner who is able to understand and evaluate the patient's situation.
- •A study partner is required:
- •1. To be healthy both physically and mentally, and
- •2. To have contact with the patient for at least 10 hours per week and be able to accompany the patient for all the visits during the participation in the study (excluding the patient's son(s) or daughter(s) living in a remote location).
- •4)Patients aged 55 years and older but younger than 84 years (at the time of informed consent).
- •5)Patients who can undergo PET scans.
排除标准
- •1)Patients who have a previous history of or are under treatment for alcoholism.
- •2)Patients who have a previous history of or are under treatment for epilepsy.
- •3)Patients who have no more than 6 years of education.
- •4)Patients with diabetes who are currently receiving insulin therapy.
- •5)Patients who are currently receiving treatment with antidepressants, antipsychotics, or long-term sedative hypnotics (including anxiolytics).
- •6)Patients who had a diagnosis of major depression or bipolar disorder within the past year, those who have a previous history of schizophrenia, or those who are considered to have difficulty in completing the protocol due to severe manifestation of psychiatric symptoms, such as anxiety or irritation, within the last 3 weeks.
- •7)Patients with concurrent serious medical conditions (such as malignancy, heart failure, liver impairment, renal impairment, or endocrine disease).
- •8)Patients with MRI evidence of local lesions, such as cerebral infarcts, which might affect cognitive function
研究者
相似试验
已完成
不适用
Multicenter study on the diagnosis of Alzheimer's disease with FDG-PET---SDAF-PET(study on diagnosis of Alzheimer's disease with FDG-PET)Alzheimer's disease, Frontotemporal lobar degenerationJPRN-UMIN000016427ational Center for Geriatrics and Gerontology138
招募中
不适用
FDG-PET in the Diagnosis of Autoimmune EncephalitisAutoimmune EncephalitisNCT06019975University of Milano Bicocca90
已完成
不适用
18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot StudyAmyloid PET ImagingNCT02556502Central Hospital, Nancy, France40
招募中
不适用
Comparison of FDG and FAPI in Patients With Various Types of CancerMetastasisTumor, SolidPositron-Emission TomographyNCT04416165The First Affiliated Hospital of Xiamen University3,000
已完成
1 期
68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CTLung TuberculosisLung CancerNCT02481726Xijing Hospital31